Advertisement
Product › Details
pharma.sensor app
Next higher product group | healthcare app (s/w) | |
Status | 2017-10-12 sales start | |
Organisation | bio.logis Genetic Information Management GmbH | |
Group | bio.logis (Group) | |
bio.logis Genetic Information Management GmbH. (10/12/17). "Press Release: bio.logis GIM Launches First Version of an iOS Mobile App for Personalized Drug Therapy".
Decisions for drugs and active ingredients depending on genetic variants / Individual drug therapies are supported
The “pharma.sensor” developed by bio.logis Genetic Information Management GmbH (bio.logis GIM) is a new mobile app for pharmacogenomics. The app shows whether certain DNA variants have to be considered for the safe efficacy of a drug. With this knowledge, the app user can identify if genotyping is useful prior of starting a drug therapy. The drug check is performed by simply entering a drug name or scanning the barcode on the packaging. The app is available in German and English via the Apple app store and is free of charge.
The DNA of every person is unique, nobody completely equals another person. This also affects the metabolism of drugs. Back in the sixties, pharmacologists found out that various human genetic variants lead to different efficacy of certain drugs. Especially antibiotics, chemotherapeutics, HIV therapeutics, oral antidiabetics, psychotropic drugs or analgesics are metabolized differently. If genetic variants are taken into consideration, recommendations for adjusting the dose or prescribing an alternative therapy can be given.
A huge amount of information about genetic variants being important for many drugs couldn’t be used in the clinical practice so far because no supporting tools have been available. Therefore, bio.logis GIM developed the “pharma.sensor” app to check whether there exists relevant DNA information for the efficacy or rather tolerance of different drugs, respectively. If so, a genetic test can be considered.
With just a few clicks, such a genetic test can be ordered directly via the “pharma.sensor” app. For this purpose, the app links to the services of the bio.logis Center for Human Genetics, a specialist for genetic analyses. Other partners will be included in the future as well.
The “pharma.sensor” app is available via the Apple App Store and can be downloaded free of charge.
A version for Android will also be available soon.
Record changed: 2017-11-14 |
Advertisement
More documents for digital health (healthcare informatics)
- [1] Mahana Therapeutics Inc.. (3/12/24). "Press Release: Mahana Therapeutics Acquires Cara Care to Become a Global Leader in the Digital Treatment of Chronic Conditions". San Francisco, CA....
- [2] Temedica GmbH. (8/2/23). "Press Release: Temedica and AbbVie Germany Are Launching Digital Companion for Patients with Chronic Inflammatory Bowel Diseases"....
- [3] High-Tech Gründerfonds Management GmbH. (7/12/23). "Press Release: Vertama Raises Seven-figure Seed Funding for Efficient, Digital Healthcare Processes". Berlin....
- [4] High-Tech Gründerfonds Management GmbH. (6/27/23). "Press Release: Doctorflix Secures €2 Million Seed Funding to Re-think Continuous Medical Education"....
- [5] SHS Gesellschaft für Beteiligungsmanagement mbH. (6/22/23). "Press Release: Healthcare Specialist SHS Capital Invests €18 Mio in MESI Medical to Bring Digital Diagnostics to the Core of Healthcare Services". Tübingen....
- [6] Bayer AG. (5/31/23). "Press Release: Digital Health Solutions to Drive Transformation of Everyday Health. Bayer Launches Unit to Develop New Precision Health Consumer Products". Basel....
- [7] Nia Health GmbH. (5/15/23). "Press Release: Using an App to Combat Skin Conditions. Nia Health Receives Millions in Funding". Berlin....
- [8] Temedica GmbH. (11/23/22). "Press Release: Temedica Raises another €25 Million in Series B Funding to Expand Its Unique Real-world Insights Ecosystem". Munich....
- [9] Xund Solutions GmbH. (9/29/22). "Press Release: Healthtech Start-up Xund Raises €6m – One of the Largest Seed Rounds to Date in Austria"....
- [10] ResMed Inc.. (8/2/22). "Press Release: ResMed Acquires Leipzig-based mementor with Insomnia Digital Health Solution somnio". Martinsried & Leipzig....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top